Autres langues Apogee Therapeutics, Inc.

Actions

APGE

US03770N1019

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 11/06/2024			Varia. 5j.	Varia. 1 janv.
43,21 ^USD	-1,57 %		-5,92 %	+54,65 %

28/05	Apogee Therapeutics, Inc. nomme Lisa Bollinger à son conseil d'administration	CI
15/05	Apogee annonce le dosage du premier patient de l'essai de phase 2 sur la dermatite atopique avec APG777, un nouvel anticorps antiIL-13 à demi-vie prolongée administré par voie sous-cutanée pour le traitement de la dermatite atopique et d'autres maladies inflammatoires.	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD	28/05
Apogee Therapeutics, Inc. Appoints Lisa Bollinger to Its Board of Directors	28/05
Apogee Therapeutics to Participate in Upcoming June Investor Conferences	23/05
Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases	15/05
Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases	15/05
Apogee Therapeutics' Q1 Net Loss Widens	13/05
Apogee Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05
Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results	13/05
Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference	06/05
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases	25/03
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody for the Treatment of Chronic Obstructive Pulmonary Disease and Other Inflammatory Diseases	25/03
Apogee Therapeutics, Inc.(NasdaqGM:APGE) added to S&P Biotechnology Select Industry Index	18/03
Apogee Closes $483 million Upsized Stock Offering	12/03
Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million	12/03
Apogee Therapeutics Prices Upsized $420 Million Share Offering	08/03
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering	08/03
Sector Update: Health Care Stocks Advance Wednesday Afternoon	06/03
Apogee Therapeutics Shares Rise After Jefferies Raises Price Target	06/03
Apogee Therapeutics Unveils $350 Million Share Offering	05/03
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering	05/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Apogee Therapeutics, Inc.

Actions

APGE

US03770N1019

Autres langues

Filtres